Background
==========

Gastrointestinal dysmotility is a common disorder in the population, especially as a complication secondary to diabetes mellitus \[[@B1]-[@B3]\]. Recently, we have shown that 63% of patients with diabetes mellitus suffer from esophageal dysmotility and 13% from gastroparesis \[[@B4]\]. Although some patients suffer from gastrointestinal symptoms, such as regurgitation, vomiting, and abdominal fullness and bloating after eating, the associations between symptoms and objective findings are poor \[[@B2]-[@B4]\]. The etiology of gastrointestinal dysmotility needs to be elucidated. Damage to interstitial cells of Cajal, loss of neuronal nitric oxide expression, hyperglycemia, vagal or autonomic neuropathy, myopathy, and abnormalities in plasma levels of several hormones have been proposed \[[@B1],[@B5]\].

Gonadotropin-releasing hormone (GnRH) is known to bind to specific receptors on the pituitary, controlling the secretion of the gonadotropins \[[@B6],[@B7]\]. However, there is growing evidence for its role as a neurotransmitter in the enteric nervous system (ENS) \[[@B8]\], where it has been shown to inhibit gastric secretion and gastrin release \[[@B9]\], stimulate enteric motility \[[@B10],[@B11]\], and inhibit cell proliferation in gastric epithelial and smooth muscle cells \[[@B12],[@B13]\]. We have recently shown that treatment with GnRH in man and rats may lead to loss of enteric neurons, with ensuing development of gastroparesis and severe dysmotility \[[@B14],[@B15]\]. Antibodies against GnRH have been observed in patients with irritable bowel syndrome (IBS), motility disorders, diabetes mellitus, and patients with functional bowel symptoms secondary to primary Sjögren's syndrome. Patients with organic gastrointestinal diseases such as inflammatory bowel disease, celiac disease, and scleroderma did not express GnRH antibodies \[[@B16],[@B17]\]. Thus, patients with diabetes mellitus frequently express antibodies against GnRH and secondary esophageal dysmotility, but the association between these two findings has to date not been examined \[[@B4],[@B17]\]. The aim of the present study was therefore to further examine the prevalence of antibodies against GnRH in patients with diabetes mellitus, with or without esophageal dysmotility or gastroparesis, to further characterize the role of the antibodies and to search for possible associations with clinical findings.

Methods
=======

This study was performed according to the Helsinki Declaration and was approved by the Regional Ethics Review Board of Lund University. All subjects gave their written, informed consent before entering the study.

Patients
--------

The inclusion criterion of the study was diabetes mellitus in patients above 18 years of age. The first patient at each consultation occasion who fulfilled this criterion when scheduled for routine clinical follow-up at the Department of Endocrinology, Skåne University Hospital, Malmö, from January 2008--February 2010, was invited to participate in the study. Exclusion criteria were severe renal failure demanding dialysis or severe cardiac diseases. At the time of the inclusion, they completed an established questionnaire with 15 symptoms related to disturbances of the gastrointestinal tract (loss of appetite, swallowing disturbances, meal-related cough, early satiety, nausea, vomiting, weight loss, abdominal fullness, bloating, regurgitation, constipation, diarrhea, evacuation incontinence, symptomatic postprandial hypoglycemia and postprandial perspiration), previously used for these patients \[[@B2]-[@B4]\]. Types and duration of diabetes mellitus, presence of diabetes complications such as retinopathy (based on fundus photography), angiopathy, microalbuminuria (measured as the albumin/creatinin quotient), albuminuria, peripheral neuropathy (examined by patellar and achilles tendon reflexes, sensitivity to vibration and monofilament test), autonomic neuropathy according to established clinical criteria (sexual dysfunction, profound sweating and orthostatic blood pressure), drug treatments, concomitant diseases, and body mass index (BMI) were all recorded by the physicians.

Glycosylated hemoglobin (HbA1c) was analyzed at the Department of Chemistry, according to clinical routines. HbA1c values were collected as Mono-S and subsequently converted to the National Glycohemoglobin Standardization Program (NGSP) standard by use of the following algorithm: 0.923 x HbA1c (Mono-S) × 1.345 = HbA1c (NGSP) \[[@B18]\]. Percentage HbA1c values were converted to the International Federation of Clinical Chemistry (IFCC) standard in mmol/mol according to the following equation: IFCC (mmol/mol) = (\[NGSP (%)\] - 2,152)/0.09148 \[[@B18]\].

The patients were referred to investigations by esophageal manometry and gastric emptying scintigraphy. If both examinations could not be performed, the patient was excluded from the study. Patients were also referred to esophagogastroduodenoscopy when clinically indicated.

Thirty-nine patients of the 55 invited completed the study and provided blood samples for analysis of GnRH antibodies, and were thus finally included in the evaluation. The most common reason not to complete the study was an inability to swallow the manometry catheter.

Esophageal manometry
--------------------

Standardized esophageal manometry was performed with an intraluminal, solid-state transducer system (Gaeltec Ltd, Isle of Skye, Scotland). Polygraph ID converter digitized the analog signal. The software was PolyGram NET (Medtronic-SynMed Medical, Stockholm, Sweden). All pressure values were expressed in mmHg and referred to atmospheric pressure. The manometry catheter was introduced through the nose and fluoroscopically positioned in the distal esophagus with the patient sitting in an upright position, which is the standard method at our laboratory. With the catheter in place, all participants were instructed to swallow 10 ml of a barium contrast medium (60% w/v). At least five barium swallows were recorded. The video fluoroscopic image and the manometry registration were mixed using a video output card (Medtronic-SynMed Medical) \[[@B2],[@B3]\]. Patients who fulfilled one or more of the following five criteria in the esophageal manometry with abnormal results were considered to suffer from esophageal dysmotility: 1: Absence of peristaltic contraction in the esophagus (aperistalsis \> 0%), 2: Mean peristaltic contraction amplitude \< 30 or \> 200 mmHg in the esophagus, 3: Percentage of simultaneous, non-propulsive peristaltic waves in the esophagus \> 10%, 4: Speed of the peristaltic wave \< 3 or \> 6 cm/s in the distal esophagus, and 5: Resting pressure in the lower esophageal sphincter (LES) \< 10 or \> 30 mmHg. Normal peristaltic activity was defined as propulsive contraction waves with peak amplitudes between 30--200 mmHg and a speed between 3--6 cm/s \[[@B2],[@B3],[@B19],[@B20]\].

Gastric emptying scintigraphy
-----------------------------

A test meal was prepared by adding tin colloid labeled with 30--50 Mbq of technetium-99 to an egg, which was whipped in a glass cup in a hot water bath until coagulated. The egg and a slice of toasted white bread were cut into pieces smaller than 1 cm × 1 cm and served with 100 ml water at 37°C. The meal was eaten within 5 min. Immediately thereafter, a large-field, double-headed gamma camera (Philips Skylight, Philips Medical Systems, Best, The Netherlands) was placed anteriorly and posteriorly parallel to the upper abdominal wall. The radioactivity was measured continuously (1-min frames) for 70 min starting immediately after meal ingestion. A Region of Interest (ROI) representing the stomach was created and the activity of the first frame was taken as 100%. The gradual decreasing radioactivity, measured as the number of radioactivity decays per minute (counts/min), was plotted against time. The time elapsed to reach a 50% decrease of the activity in the ROI (T~50~) was identified as the point at which this plot crossed the 50% value. The values of the radioactivity measured were corrected for the half-life of ^99m^Tc, and for attenuation by using the geometrical mean values of the decay curves obtained from the two gamma camera heads used. T~50~ \> 2 standard deviations ([sd)]{.smallcaps} for healthy control subjects (70 min) was considered abnormal \[[@B21]\].

Measurement of human antibodies against gonadotropin-releasing hormone
----------------------------------------------------------------------

Blood samples were drawn from patients and the serum was separated and kept frozen at -20°C until analyzed. Analysis of anti-GnRH antibodies was carried out by an ELISA slightly modified on the basis of the results described in previous studies \[[@B8],[@B16]\]. The wells of micro titer plates were coated with human GnRH (L7134, Sigma, St Louis, MO, USA) for an overnight incubation at 4°C and thereafter the plastic wells were blocked with 0.5% fish gel solution (G7765, Sigma) in PBS containing 0.05% Tween-20 (PBS-T). Serial dilutions of patient serum (1/100, 1/500 and 1/2500 in PBS-T) were then added to the plates and incubated for 2 h at room temperature (RT) and overnight at 4°C. After rinsing with PBS-T, deposition of autoantibodies directed to GnRH was detected using biotinylated rabbit anti-human IgM (673211, MP Biomedicals, Solon, OH, USA) or IgG antibodies (ab7159, ABcam, Cambridge, MA, USA) appropriately diluted in PBS-T. After another incubation for 2 h at RT, the plates were washed and the bound, biotinylated antibodies detected by alkaline phosphatase-conjugated streptavidin (405211, Biolegend, San Diego, CA, USA), incubated for 1 h at RT. To develop a color reaction a phosphatase substrate kit (37620, Pierce, Rockford, Ill, USA) was used. The absorbance at 405 nm was measured after 2 h of incubation at RT. A plasma pool from healthy blood donors was included on each ELISA plate for measurements of the variation. The plasma pool was used for the calculation of the intra-assay and inter-assay coefficient of variation, which was 11.5% and 16.1%, respectively, for IgM and 11.5% and 25.4%, respectively, for IgG. Antibody levels are presented as relative units (RU) (absorbance values after subtraction of background levels and multiplied by 100). Relative units over 0 were considered as a positive antibody level \[[@B17]\].

The controls were chosen from a cohort of healthy blood donors previously described in detail \[[@B17]\]. Over a period of five months (October 1996--February 1997), blood donors were offered antibody screening for gastrointestinal diseases. To be able to include all blood donors in Malmo, sera from male donors were collected over a 3-month period and from female donors over a 4-month period (in accordance with their regular donation intervals). A total of 1,970 donors were included. During this period, 2,135 blood donations took place, which means that at least 92% of donors agreed to be included. From this sample cohort, 50 men and 50 women from each 10-year age span period, between 20 and 70 years of age, were randomly included. As few blood donors above 60 years of age, only 16 women and 40 men were included in the age group 60--70 years. In total, 456 controls were examined during the same time period as the patients. From this cohort, two age- and gender-matched controls were randomly extracted for each patient in this study.

Statistical analyses
--------------------

The data were analyzed using the statistical software package SPSS for Windows^©^ (Release 20.0; IBM). All variables were analyzed for normal distribution by Kolmogorov-Smirnov test. Group-wise differences between patients and controls were tested by using the unpaired Student's *t*-test and, when normality was rejected (antibody levels), the Mann-Whitney *U*-test was used. Fisher's exact test was used for dichotomized variables. Correlations were calculated by Spearman rank correlation test. Values are expressed as mean ± standard deviation (SD) or median, interquartile range (IQR). Binary logistic regression analysis was performed to test for an association between the presence of antibodies against GnRH (dependent variable) and clinical findings in patients. Independent variables were age (years), gender, type of diabetes, duration of disease (years), BMI (kg/m^2^), HbA1c (mmol/mol), esophageal and gastric dysmotility, secondary complications, and symptoms, examined as univariate analysis. No presence of antibodies, symptoms or pathological findings was used as reference. P \< 0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

Thirty-nine patients with diabetes mellitus (27 females), age 52.4 ± 12.5 years, were included. All the patients were insulin-treated, and were in acceptable metabolic control (Table [1](#T1){ref-type="table"}). Esophageal dysmotility was more common (69%) than gastroparesis (18%). Retinopathy was the most common diabetes complication (72%) (Table [1](#T1){ref-type="table"}). Although the patients were included regardless of the presence of gastrointestinal symptoms, the majority of patients reported some sort of symptoms related to the gastrointestinal tract and food intake (Table [2](#T2){ref-type="table"}).

###### 

The associations between characteristics in patients with diabetes mellitus and the presence of antibodies against gonadotropin-releasing hormone (GnRH) in serum

                                        **Patients**    **GnRH IgM −/+**        **GnRH IgG −/+**
  ------------------------------------- --------------- ----------------------- -----------------------
  **Age** (years)                       52.4 ± 12.5     1.469 (0.927-1.034)     0.019 (0.964--1.127)
  **Gender** (Female/male) n (%)        27(69)/12(31)   1.696 (0.413-1.976)     2.667 (0.452--15.722)
  **Type of diabetes** (1/2)            36/3            1.00 (0.082--12.164)    3.100 (0.235--40.895)
  **Duration of the disease** (years)   26.3 ± 13.1     0.654 (0.940--1.042)    0.048 (0.974--1.126)
  **BMI** (kg/m^2^)                     26.5 ± 5.8      0.835 (0.699--0.998)    1.103 (0.958--1.269)
  **HbA1c** (mmol/mol)                  65.9 ± 9.9      0.983 (0.917--1.053)    0.968 (0.880--1.063)
  **Esophageal dysmotility** n (%)                                              
  No (reference)                        12 (31)         1.000                   1.000
  Yes                                   27 (69)         0.589 (0.143--2.424)    2.500 (0.259--24.096)
  **Gastric dysmotility** n (%)                                                 
  No (reference)                        32 (82)         1.000                   \-
  Yes                                   7 (18)          3.407 (0.633--18.35)    \-
  **Retinopathy** n (%)                                                         
  No (reference)                        11 (28)         1.000                   1.000
  Yes                                   28 (72)         0.829 (0.192--3.577)    2.174 (0.224--21.079)
  **Angiopathy** n (%)                                                          
  No (reference)                        26 (67)         1.000                   1.000
  Yes                                   13 (33)         0.480 (0.106--2.179)    0.350 (0.036--3.358)
  **Microalbuminuria** n (%)                                                    
  No (reference)                        35 (90)         \-                      1.000
  Yes                                   4 (10)          \-                      7.750 (0.842--71.314)
  **Macroalbuminuria** n (%)                                                    
  No (reference)                        36 (92)         1.000                   1.000
  Yes                                   3 (8)           4.545 (0.372--55.542)   3.100 (0.235--40.895)
  **Autonomic neuropathy** n (%)                                                
  No (reference)                        29 (74)         1.000                   1.000
  Yes                                   10 (26)         1.481 (0.334--6.572)    9.000 (1.327--61.025)
  **Peripheral neuropathy** n (%)                                               
  No (reference)                        20 (51)         1.000                   1.000
  Yes                                   19 (49)         0.857 (0.226--3.254)    1.062 (0.187--6.052)

*BMI* Body mass index, *HbA1c* Glycosylated hemoglobin. Values are given as mean ± standard deviation (SD) or n (%). *OR* Odds ratio, *CI* Confidence interval, - = calculations not possible to carry out due to a low number of patients. In the statistical calculations, patients were divided into those with and without (reference) antibodies.

###### 

The association between various symptoms in patients with diabetes mellitus and the presence of antibodies against gonadotropin-releasing hormone (GnRH) in serum

  **Symptoms**                                **Patients (N = 39)**   **GnRH IgM −/+**        **GnRH IgG −/+**
  ------------------------------------------- ----------------------- ----------------------- -----------------------
  **Loss of appetite**                                                                        
  No (reference)                              31 (80)                 1.000                   1.000
  Yes                                         8 (20)                  4.792 (0.928--24.750)   0.743 (0.074--7.436)
  **Swallowing disturbances**                                                                 
  No (reference)                              32 (82)                 1.000                   1.000
  Yes                                         7 (18)                  0.764 (0.127--4.596)    0.900 (0.088--9.178)
  **Meal-related cough**                                                                      
  No (reference)                              33 (85)                 1.000                   1.000
  Yes                                         6 (15)                  1.000 (0.158--6.330)    3.625 (0.494--26.611)
  **Early satiety**                                                                           
  No (reference)                              24 (62)                 1.000                   1.000
  Yes                                         15 (38)                 0.606 (0.148--2.486)    0.769 (0.123--4.821)
  **Nausea**                                                                                  
  No (reference)                              28 (72)                 1.000                   1.000
  Yes                                         11 (28)                 0.343 (0.062--1.898)    0.460 (0.047--4.460)
  **Abdominal fullness**                                                                      
  No (reference)                              23 (59)                 1.000                   1.000
  Yes                                         16 (41)                 0.300 (0.067--1.347)    0.240 (0.025--2.286)
  **Bloating**                                                                                
  No (reference)                              19 (49)                 1.000                   1.000
  Yes                                         20 (51)                 0.278 (0.067--1.147)    0.941 (0.165--5.361)
  **Regurgitation**                                                                           
  No (reference)                              27 (69)                 1.000                   1.000
  Yes                                         12 (31)                 0.114 (0.013--1.009)    2.667 (0.452--15.722)
  **Constipation**                                                                            
  No (reference)                              28 (72)                 1.000                   1.000
  Yes                                         11 (28)                 0.675 (0.145--3.135)    0.460 (0.047--4.460)
  **Diarrhea**                                                                                
  No (reference)                              33 (85)                 1.000                   1.000
  Yes                                         6 (15)                  1.000 (0.158--6.330)    1.120 (0.107--11.726)
  **Symptomatic postprandial hypoglycemia**                                                   
  No (reference)                              30 (77)                 1.000                   1.000
  Yes                                         9 (23)                  0.764 (0.127--4.596)    0.900 (0.088--9.178)
  **Postprandial perspiration**                                                               
  No (reference)                              34 (87)                 1.000                   1.000
  Yes                                         5 (13)                  1.394 (0.203--9.585)    1.450 (0.133--15.793)

*n* number, *OR* Odds ratio, *CI* Confidence interval. In the statistical calculations, patients were divided into those with and without (reference) antibodies.

Antibodies against gonadotropin-releasing hormone
-------------------------------------------------

The prevalence of IgM antibodies in patients with diabetes mellitus was 33%, to be compared with 14% in controls (p = 0.027), with a higher titer level in the patients (p = 0.000). The prevalence of IgG antibodies in patients was 15% and none in the controls (p = 0.000) (Table [3](#T3){ref-type="table"}). There was no association between the expression of IgM and IgG antibodies (p = 0.631), but one or both of these antibodies were found in 17 of 39 patients (44%) compared with 11 of 78 controls (14%) (p = 0.001). None of the secondary complications or symptoms was associated with the presence of IgM antibodies (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). The prevalence of vomiting (n = 2), weight loss (n = 1), and evacuation incontinence (n = 2) was too low to allow calculations. The only variable associated with IgM antibodies was BMI, with lower BMI being associated with an increased prevalence of antibodies (OR = 0.835, 95% CI = 0.699--0.998). Presence of autonomic neuropathy was the only variable associated with IgG antibodies (OR = 9.000, 95% CI = 1.327--61.025). Esophageal dysmotility or gastroparesis were not associated with the presence of IgM antibodies (OR = 0.589, 95% CI = 0.143--2.424 and OR = 3.407, 95% CI = 0.633--18.350, respectively). Neither was esophageal dysmotility associated with the presence of IgG antibodies (OR = 2.500, 95% CI = 0.259--24.096). Association between gastroparesis and the presence of IgG antibodies was not able to calculate (Table [1](#T1){ref-type="table"}). There were no differences in gastric emptying rate or age between patients who did or did not express IgM or IgG antibodies (p = 0.059 vs. p = 0.538 and p = 0.466 vs. p = 0.303, respectively). There was no correlation between the level of IgM or IgG antibodies and gastric emptying rate (p = 0.602 and p = 0.700, respectively). Neither did the level of IgM or IgG antibodies correlate to esophageal aperistalsis (p = 0.268 and p = 0.518, respectively), mean peristaltic contraction amplitude (p = 0.275 and p = 0.156, respectively), percentage of simultaneous, non-propulsive peristaltic waves (p = 0.955 and p = 0.441, respectively), speed of the peristaltic wave (p = 0.603 and p = 0.493, respectively) or resting pressure in the lower esophageal sphincter (p = 0.562 and p = 0.827, respectively).

###### 

Levels of antibodies against gonadotropin-releasing hormone (GnRH) in serum in patients and controls

                                        **Diabetes mellitus**   **Controls**    **P-value**
  ------------------------------------- ----------------------- --------------- -------------
  **Prevalence IgG antibodies n** (%)   6 (15)                  0               0.000
  **Level of IgG antibodies** (RU)      2.4 (0.4-1.9)           \*              \-
  **Prevalence IgM antibodies n** (%)   13 (33)                 11 (14)         0.027
  **Level of IgM antibodies** (RU)      1.2 (0.6-5.0)           0.2 (0.1-0.3)   0.000

Antibody levels are presented as relative units (RU), median (interquartile range). n (%) = number and percentage of subjects. \* = no IgG antibodies were found. Mann-Whitney *U-* test or Fisher's exact test. P \< 0.05 was considered statistically significant.

Discussion
==========

The present study showed that patients with diabetes mellitus expressed antibodies against GnRH in serum. The result confirms previous findings of presence of GnRH antibodies in patients expressing a high prevalence of gastrointestinal symptoms and dysmotility and/or diabetes mellitus \[[@B17]\]. Apart from a weak association between the presence of IgM antibodies and lower BMI, and an association between the presence of IgG antibodies and autonomic neuropathy, no other associations with the antibody expression were found.

Gonadotropin-releasing hormone is secreted by the hypothalamus and its most important effect is on the pituitary, stimulating gonadotropin synthesis and secretion. It is a crucial hormone in reproductive physiology and sexual behavior \[[@B6]\]. Peripherally, GnRH and GnRH receptors have been found in the rat myenteric plexus and the intestinal epithelium \[[@B22],[@B23]\], and GnRH has been described in human myenteric neurons \[[@B8]\]. Gonadotropin-releasing hormone has been shown to inhibit the release of gastric secretion and gastrin release in dog \[[@B9]\], and to stimulate motor function in the gastrointestinal tract in female rats and in a patient suffering from chronic intestinal pseudo-obstruction \[[@B10],[@B11]\]. Furthermore, GnRH antibodies have been shown to have anti-proliferative effects on epithelial and smooth muscle cells \[[@B12],[@B13]\] and gastrointestinal tumor cell lines \[[@B24],[@B25]\]. In another study, the GnRH receptor has been found on murine endometrium mediating apoptosis \[[@B26]\]. Thus, GnRH may affect growth regulation of gastrointestinal structures.

We have now repeatedly described that patients with IBS and dysmotility express GnRH antibodies \[[@B8],[@B16],[@B17]\], but the effect of GnRH and/or its antibodies on the physiology and pathophysiology of the gastrointestinal tract remains to be determined. In our previous report, the titer of antibodies, but not the prevalence, was higher in patients compared with controls \[[@B17]\]. This is in contrast with the present findings of an increased prevalence of antibodies in relation to diabetes mellitus. This discrepancy may be explained by the low number of patients examined in the former study, with a greater percentage of females (20 patients, 11 females) \[[@B17]\]. Nevertheless, there was an enhanced expression of GnRH antibodies in both studies in relation to diabetes mellitus. A recent report showed a significant effect of the intestinal GnRH mRNA level on blood glucose levels, indicating that GnRH may be of importance for glucose homeostasis \[[@B27]\]. Moreover, development of diabetes mellitus and autoimmune thyroiditis has been reported after long-term administration of GnRH \[[@B28]\].

In the present study, lower BMI in diabetes mellitus was associated with the expression of IgM antibodies. We have little knowledge about the exact mechanisms of appetite and body weight regulation, but a range of different peptide hormones and neuropeptides seems to be involved \[[@B29]\]. It is recognized that appropriate regulation of reproduction, energy intake, and energy expenditure, and thus maintenance of body weight and fertility, relies on complex hypothalamic neurocircuitry \[[@B30]\]. Food intake and the reproductive function are closely linked. The presence of autoantibodies against melanocyte-stimulating hormone has been documented in healthy man and rat. These antibodies, and other autoantibodies, could be involved in the regulation of feeding, but could also influence the level of anxiety. The authors conclude that autoantibodies against appetite-regulating neuropeptides and peptide hormones may be important participants in mechanisms controlling appetite and food intake \[[@B31]\]. Antibodies against GnRH may pass the blood brain barrier (BBB) and could hypothetically affect appetite-regulating structures in the hypothalamus. Furthermore, the peripheral release of appetite-regulating neuropeptides and peptide hormones from the gastrointestinal tract may be regulated by GnRH present in the ENS \[[@B8],[@B22],[@B23],[@B32]\].

Repeated treatment with GnRH has been shown to render enteric dysmotility and antibodies against GnRH in serum in some cases \[[@B14]\]. The antibodies are assumed to be secondary to the dysmotility, reflecting neuronal damage \[[@B14]\]. Gastrointestinal dysmotility is associated with autonomic neuropathy \[[@B33]\]. Thus, the association between IgG antibodies and autonomic neuropathy in this study may reflect an association between gastrointestinal neuron damage in ENS and autonomic neuropathy. On the contrary, a few studies have reported the presence of antibodies in serum in patients with autonomic neuropathy, so the antibodies may reflect neuronal damage in the autonomic nervous system as well \[[@B34],[@B35]\]. We do not know the difference between the expression of IgM and IgG antibodies in the patients with diabetes mellitus. Probably, the expression of IgM antibodies is persisting in this entity, as the patients had had duration of diabetes mellitus for several years, before inclusion in the study.

One of the limitations of this study is the small sample size. However, we need to perform small pilot studies before testing our hypothesis in greater cohorts with hundreds of patients. Another limitation is that the motility of the lower gastrointestinal tract was not examined, and that the manometry was carried out only over a short time span. If an ambulatory manometry for 24 h had been used, associations may have been found. We chose to examine the patients with as few examinations as possible, to diminish the burden on the patients, and to be able to include more patients. In future studies, it seems more relevant to focus on esophageal manometry examination than on gastric emptying scintigraphy, which seems to be a smaller problem among these patients. The test method needs to be further evaluated concerning the optimal cut-off level. In our ELISA, we considered all relative antibody units above zero as expression of antibodies. If a higher baseline level of antibodies present in serum had been regarded as expression, almost all controls would have been below this cut-off. When more patients have been studied, the cut-off level for positive expression should be redefined.

Conclusions
===========

Patients with diabetes mellitus express antibodies against GnRH in serum. Apart from weak associations between the presence of IgM antibodies and lower BMI, and IgG antibodies and autonomic neuropathy, no other associations with the antibody expression are found.
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